| Ytd | 8.43% | |
| 1y | 640.33% |
| Open | 330.89 | Prev Close | 334.79 | Low | 312.05 | High | 337.72 | Mkt Cap | 8.91B |
| Vol | 607.03K | Avg Vol | 494.92K | EPS | -13.39 | P/E | N/A | Forward P/E | -35.69 |
| Beta | 2.75 | Short Ratio | 7.27 | Inst. Own | 116.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 314.75 | 200-d Avg | 256.51 | 1yr Est | 619.78 |
PRAX News
FDA sets updated PDUFA date of December 27, 2026BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Pre
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Pr
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises
FDA grants Breakthrough Therapy Designation to Praxis' elsunersen after strong seizure reduction
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system
RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX)
Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a
Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy an
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and
HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) wi
Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose
BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary succes
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) w
BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maint
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform
BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maint
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.20) per share which beat th
Praxis (PRAX) shares jump as FDA accepts NDA for ulixacaltamide in essential tremor. Target action d
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maint
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) w
BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maint
Praxis Precision Medicines shares are trading higher Monday after it announced positive results from
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015)71% of elsu
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,
Wolfe Research analyst Rudy Li initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with
Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equ
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and
Truist Securities analyst Joon Lee maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy a
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.50) per share which missed
Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises
Wells Fargo analyst Benjamin Burnett initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX
HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) wi
Piper Sandler analyst Yasmeen Rahimi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Ove